Skip to main content

Table 1 Baseline characteristics of all PMN patients and subgroups classified into ET, PMF and PV syndrome

From: Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms

Clinical characteristics

PMN (n = 105)

ET (n = 67)

PV (n = 16)

PMF (n = 22)

P a

Gender - male (%)

77 (73.3)

50 (74)

10 (62.5)

17 (77.3)

NS

Age (years)

64 (16–96)

64 (16–96)

69 (29–86)

57 (29–85)

NS

WBC (× 103/mL)

14.3 (1.9–87.2)

14.8 (6.8–66.5)

8.2 (5.2–31.9)

15.5 (1.9–87.2)

0.039

RBC (× 106/mL)

4.8 (2.1–9.7)

4.5 (2.5–8.1)

5.7 (5.4–9.7)

4.5 (2.14–9.7)

0.0002

PLT(×103/mL)

710 (45–2301)

820 (376–2301)

233 (150–803)

246 (45–1776)

6.15e-11

Hb (g/L)

138 (10.5–211)

132 (10.5–188)

185 (167–211)

125 (66–178)

2.17e-08

  1. Abbreviation: Hb, hemoglobin; PLT, platelets; WBC, white blood cell; RBC, red blood cell; NS, not significant. Values given are medians and range. (a) in comparison between subgroups (ET, PV and PMF). P values were calculated by Chi-squared and Kruskal-Wallis test where appropriate